Please note, this OEL/ADE monograph also applies to atosiban acetate (CAS RN 914453-95-5), an oxytocin and vasopressin antagonist, was initially investigated as a treatment for dysmenorrhea and is indicated to delay imminent pre-term birth in pregnant adult women with regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes, a cervical dilation of 1 to 3 cm or 0-3 for expecting mothers who have never given birth in the past (nulliparas) and effacement of ≥ 50%, a gestational age from 24 until 33 completed weeks, and a normal fetal heart rate.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Atosiban, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.